Microdosing Semaglutide Schedule: How Providers Actually Build One

Semaglutide's standard schedule is printed right on the Wegovy label: 0.25 mg weekly for a month, then up a fixed ladder to a 1.7 or 2.4 mg maintenance dose.^[1] A microdosing schedule simply ignores that destination. It starts at or below the bottom rung, climbs slowly if it climbs at all, and aims for the smallest dose that keeps your appetite and your weight where you want them. If it's the dose amounts themselves you're looking for, our microdosing semaglutide chart is the companion to this guide.

What a Microdosing Schedule for Semaglutide Is

A microdosing schedule is a plan that deliberately stays below the standard ladder, aiming for the lowest dose that does what you need it to do. The label's schedule exists to deliver you to 2.4 mg, the dose that produced roughly 15% average weight loss in trials,^[1][3] and everything about its pacing serves that destination. A microdosing plan trades the destination for a question: what if a fraction of that dose is all your body actually needs?

Here's the detail most articles gloss over. The label treats 0.25 mg strictly as a starting dose, with maintenance defined as 1.7 or 2.4 mg,^[1] so a plan that stays at the bottom, or below it, is by definition a provider's judgment call made outside the printed schedule. That isn't a scandal, since providers make judgment calls constantly, but it does mean the quality of a microdosing schedule depends entirely on the quality of the judgment behind it. Typical territory runs from about 0.1 to 0.5 mg weekly, and while the 0.25 and 0.5 mg levels exist as standard pens, anything below that is prescribed as personalized compounded semaglutide, documented for you specifically.^[6]

The Structure: Start Low, Hold Long, Move on Signals

Provider-built semaglutide schedules follow the same three rules as their tirzepatide counterparts, so if you've read that guide, this will feel familiar.

Start at or below the bottom rung. For maintenance after a loss, or for appetite control in a woman who's never used a GLP-1, starting points of 0.1 to 0.25 mg are common, and women who had rough side effects on standard dosing often restart lower than wherever they left off.

Hold each level 4 to 8 weeks or longer. Semaglutide takes 4 to 5 weeks to reach steady levels in your body, so judging a dose in week two is judging it early. The questions at each hold are simple ones: is appetite quiet, is the trend flat or moving the way you want, and are the side effects tolerable?

Move only on signals. Up if food noise returns or the maintenance trend drifts for several consecutive weeks; down, or onto a stretched interval, if side effects show up or the effect is stronger than you need. The best schedule is honestly a boring one, all long holds and small moves and no drama, which is precisely what you want from a maintenance plan.

Why Midlife Schedules Run Lower and Slower

Because midlife biology gives them two good reasons to. The first is response: when researchers went back and split semaglutide trial results by sex, women had lost a greater percentage of body weight than men at the same dose.^[8] A stronger response means the standard ladder can overshoot, delivering more loss than you wanted and more nausea than anyone wants, so for many women a lower schedule isn't a compromise at all. It's the right-sized dose.

The second is that perimenopause refuses to hold still. Appetite, sleep, and stress hormones shift month to month, and those shifts show up in how a fixed dose feels. A schedule with built-in review absorbs that variability, a set-and-forget prescription doesn't, and if you take hormone therapy, the review should cover both medications together.

The Honest Evidence Picture

The full-dose evidence is excellent, and the microdose evidence doesn't exist yet, which is the whole picture in one sentence. STEP 1 delivered about 15% average body-weight loss at 2.4 mg over 68 weeks.^[3] STEP 4 then showed that people switched to placebo after five months regained most of the loss while those who continued kept losing, the clearest proof we have that ongoing medication is what maintains results.^[4]

But nobody has run the trial on 0.1 or 0.25 mg schedules for maintenance, a point a Harvard endocrinologist made publicly this year in unusually plain language: no legitimate long-term data, and no agreed definition of microdosing at all.^[2] One registered trial is finally underway.^[5] Until it reports, a semaglutide microdosing schedule is an educated bridge from what's proven: the full-dose evidence and the drug's known behavior in the body, applied conservatively to a lower range, with monitoring doing the work the missing trial would have done. That last clause is why the provider isn't optional.

Getting Your Schedule

Expect a provider to ask about your goal (maintaining, appetite control, or slow loss), the doses you've used and how they felt, where you are in the menopause transition, and what else you're taking. Those answers become a starting dose, a hold plan, and scheduled check-ins where the dose either earns its place or gets changed.

Next reads: the semaglutide chart for the monthly framework, and what GLP-1 microdosing is for the full picture. When you're ready for the version built around your own body, Josie's microdose maintenance plans start with that provider review.